ES2920823T3 - Inhibidores bicíclicos de la urea quinasa y usos de los mismos - Google Patents

Inhibidores bicíclicos de la urea quinasa y usos de los mismos Download PDF

Info

Publication number
ES2920823T3
ES2920823T3 ES17740232T ES17740232T ES2920823T3 ES 2920823 T3 ES2920823 T3 ES 2920823T3 ES 17740232 T ES17740232 T ES 17740232T ES 17740232 T ES17740232 T ES 17740232T ES 2920823 T3 ES2920823 T3 ES 2920823T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
certain embodiments
disease
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17740232T
Other languages
English (en)
Spanish (es)
Inventor
Nathanael Gray
Yanke Liang
Hwan Choi
Thomas Sundberg
Alykhan Shamji
Ramnik Xavier
David E Fisher
Nisma Mujahid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2920823T3 publication Critical patent/ES2920823T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES17740232T 2016-07-05 2017-07-05 Inhibidores bicíclicos de la urea quinasa y usos de los mismos Active ES2920823T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358524P 2016-07-05 2016-07-05
PCT/US2017/040722 WO2018009544A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
ES2920823T3 true ES2920823T3 (es) 2022-08-10

Family

ID=59351134

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17740232T Active ES2920823T3 (es) 2016-07-05 2017-07-05 Inhibidores bicíclicos de la urea quinasa y usos de los mismos

Country Status (10)

Country Link
US (3) US10954242B2 (enExample)
EP (2) EP3481830B1 (enExample)
JP (1) JP7277357B2 (enExample)
KR (1) KR20190075043A (enExample)
CN (1) CN110225914A (enExample)
AU (1) AU2017291812B2 (enExample)
CA (1) CA3069016A1 (enExample)
ES (1) ES2920823T3 (enExample)
IL (1) IL264106B (enExample)
WO (1) WO2018009544A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
JP7277357B2 (ja) 2016-07-05 2023-05-18 ザ ブロード インスティテュート，インコーポレーテッド 二環式尿素キナーゼインヒビターおよびそれらの使用
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
KR20190120331A (ko) * 2017-02-28 2019-10-23 더 제너럴 하스피탈 코포레이션 Sik 억제제로서의 피리미도피리미디논의 용도
UA127059C2 (uk) * 2018-03-30 2023-03-29 Ле Лаборатуар Сервьє Гетеробіциклічні інгібітори mat2a і способи використання для лікування злоякісної пухлини
WO2020027200A1 (ja) * 2018-08-01 2020-02-06 小野薬品工業株式会社 軟骨関連疾患治療剤
US20230027026A1 (en) * 2019-09-27 2023-01-26 Jubilant Biosys Limited Fused pyrimidine compounds, compositions and medicinal applications thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
US12195490B2 (en) * 2020-01-30 2025-01-14 The Regents Of The University Of California STRAD-binding agents and uses thereof
CA3177164A1 (en) * 2020-04-28 2021-11-04 Peter Sennhenn Bicyclic kinase inhibitors and uses thereof
EP4149629B1 (en) 2020-05-14 2025-06-04 Rhizen Pharmaceuticals AG Purine derivatives as sik-3 inhibitors
EP4215533A4 (en) * 2020-09-16 2024-12-18 Axceso Biopharma Co., Ltd. Pyrimidopyrimidinone compound and pharmaceutical composition comprising same
US20230265099A1 (en) * 2020-09-21 2023-08-24 Soltego, Inc. Sik inhibitors and methods of use thereof
CN116801878A (zh) * 2020-10-05 2023-09-22 达纳-法伯癌症研究所股份有限公司 Her2的有效和选择性抑制剂
US20240100177A1 (en) * 2020-12-04 2024-03-28 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
WO2022165530A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
KR20230053049A (ko) * 2021-10-13 2023-04-21 서울대학교산학협력단 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
CN117547615B (zh) * 2023-09-26 2024-12-06 首都医科大学宣武医院 一种纳米囊泡及其制备方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4231559B2 (ja) 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
IL139599A0 (en) 1998-05-26 2002-02-10 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
CA2347474C (en) 1998-10-23 2008-08-26 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
WO2003090688A2 (en) 2002-04-24 2003-11-06 Van Andel Research Institute Enhancement of human epidermal melanogenesis
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US20060094013A1 (en) 2002-08-21 2006-05-04 Hiroshi Takemori Salt-inducible kinases 2 and use thereof
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
MXPA05005547A (es) 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
EP1615928A1 (en) 2003-04-10 2006-01-18 F.Hoffmann-La Roche Ag Pyrimido compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
AU2004260689B8 (en) * 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
US7745437B2 (en) 2004-06-10 2010-06-29 Irm Llc Compounds and compositions as protein kinase inhibitors
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0514738A (pt) 2004-08-31 2008-06-24 Hoffmann La Roche derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2006074057A2 (en) 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
JP2008537937A (ja) 2005-03-25 2008-10-02 グラクソ グループ リミテッド ピリド［２，３−ｄ］ピリミジン−７−オンおよび３，４−ジヒドロピリミド［４，５−ｄ］ピリミジン−２（１Ｈ）−オン誘導体の製造方法
MX2007015610A (es) * 2005-06-10 2008-02-21 Irm Llc Compuestos que mantienen la fluripotencia de las celulas totipotentes embrionarias.
EA016438B1 (ru) 2005-12-21 2012-05-30 Новартис Аг Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов (fgf-фактора)
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
WO2009073153A2 (en) 2007-11-28 2009-06-11 Dana Farber Cancer Institute Small molecule myristate inhibitors of bcr-abl and methods of use
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
WO2009152027A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
US8455477B2 (en) 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
JP2012511501A (ja) * 2008-12-12 2012-05-24 Ｍｓｄ株式会社 ジヒドロピリミドピリミジン誘導体
EP2488526B1 (en) 2009-10-14 2013-07-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
CA2849999A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
SI3459942T1 (sl) 2012-04-24 2021-05-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
GB201212960D0 (en) * 2012-07-20 2012-09-05 Common Services Agency Erythroid production
JP5683634B2 (ja) * 2012-11-28 2015-03-11 株式会社ショーワ 圧力緩衝装置
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
SG11201507478VA (en) * 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
CN105209040A (zh) 2013-03-15 2015-12-30 昂科迪塞恩股份有限公司 大环的盐可诱导的激酶抑制剂
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) 2014-07-21 2022-08-16 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
CA2955082A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
KR101850282B1 (ko) 2014-11-26 2018-05-31 한국과학기술연구원 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
CN104482860B (zh) 2014-12-05 2017-10-31 浙江大学宁波理工学院 鱼类形态参数自动测量装置和方法
JP7277357B2 (ja) 2016-07-05 2023-05-18 ザ ブロード インスティテュート，インコーポレーテッド 二環式尿素キナーゼインヒビターおよびそれらの使用
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
KR20190120331A (ko) 2017-02-28 2019-10-23 더 제너럴 하스피탈 코포레이션 Sik 억제제로서의 피리미도피리미디논의 용도

Also Published As

Publication number Publication date
IL264106A (en) 2019-01-31
AU2017291812A1 (en) 2019-02-21
WO2018009544A1 (en) 2018-01-11
US20200317675A9 (en) 2020-10-08
US20210147425A1 (en) 2021-05-20
KR20190075043A (ko) 2019-06-28
EP4047001A2 (en) 2022-08-24
AU2017291812B2 (en) 2023-12-14
US12398145B2 (en) 2025-08-26
EP3481830A1 (en) 2019-05-15
US20230234959A1 (en) 2023-07-27
CA3069016A1 (en) 2018-01-11
CN110225914A (zh) 2019-09-10
EP4047001A3 (en) 2022-11-30
JP7277357B2 (ja) 2023-05-18
IL264106B (en) 2022-04-01
JP2019527682A (ja) 2019-10-03
US20190315752A1 (en) 2019-10-17
EP3481830B1 (en) 2022-02-16
US11725011B2 (en) 2023-08-15
US10954242B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
ES2920823T3 (es) Inhibidores bicíclicos de la urea quinasa y usos de los mismos
US12209076B2 (en) Imidazolyl kinase inhibitors and uses thereof
EP3172213B1 (en) Macrocyclic kinase inhibitors and uses thereof
CN106715437A (zh) 二氮杂环庚烷衍生物及其用途
AU2016319785A1 (en) Acetamide thienotriazoldiazepines and uses thereof
AU2016319116A1 (en) Cyano thienotriazolodiazepines and uses thereof
CN106793775A (zh) 二氢碟啶酮衍生物及其用途
HK40070345A (en) Bicyclic urea kinase inhibitors and uses thereof
HK40008957B (en) Bicyclic urea kinase inhibitors and uses thereof
EP4601637A2 (en) Glycogen synthase kinase 3 inhibitors and uses thereof